Browse studies

Find your next paid study

6 recruiting studies matching your filters

A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

The purpose of this study is to evaluate how well each individual dose of esketamine (56 milligrams \[mg\] and 84 mg) works when compared with placebo in impro…

Depressive Disorder, Treatment-Resistant

Estimated

~$10 – $8,750

Janssen Research & Development, LLCNCT07716098

Phase 2

An Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

Background: Major depressive disorder (MDD) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat MDD, …

SuicideDepressive Disorder, Treatment-ResistantKetamine+10 more

Estimated

~$10 – $5,625

National Institute of Mental Health (NIMH)NCT06511908

Phase 2

A Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of ACP-211 Monotherapy in Adults With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant the…

Major Depressive Disorder (MDD)Depressive Disorder, Treatment-Resistant

Estimated

~$10 – $8,750

ACADIA Pharmaceuticals Inc.NCT07284667

Observational

One-Day cTBS Over the Precuneus (OcTOPUS)

The goal of this clinical trial is to learn whether two forms of one-day accelerated transcranial magnetic stimulation (TMS) can reduce depressive symptoms in …

Depressive Disorder, Treatment-ResistantTreatment Resistant Depression (TRD)Treatment Resistant Major Depression Disorder

Estimated

~$10 – $6,250

Mclean HospitalNCT07758010

Phase 2

Central and Peripheral GABA and Glutamate Modulation With Intravenous Ketamine for Treatment-Resistant Depression (G2K): A Randomized, Double-Blind, Placebo-Controlled Study

The purpose of this study is to to evaluate the relationships between peak (% change from baseline) central GABA and Glu levels during a 40-min IV ketamine or …

Depressive Disorder, Treatment-ResistantTreatment Resistant Depression (TRD)

Estimated

~$10 – $6,250

Mayo ClinicNCT06668571

Phase 1

NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits

Most clinical major depression responds to standard treatments (medication and psychotherapy); however, a significant subset of depressed patients (15-20%) do …

Depressive Disorder, MajorDepressive Disorder, Treatment-Resistant

Estimated

~$10 – $6,250

Washington University School of MedicineNCT02994433